Literature DB >> 12235515

Angioneurotic edemas of the upper aerodigestive tract after ACE-inhibitor treatment.

M Tisch1, L Lampl, A Groh, H Maier.   

Abstract

There are rare cases in which inhibitors of the angiotensin-converting enzyme can cause an angioneurotic edema of the upper aerodigestive tract. The pathomechanism of this side effect depends on an interaction of the drug with hormones regulating vascular permeability, such as the kallikrein kinin system and the prostaglandin system. Angioedema is characterized by subcutaneous or submucosal swellings, which usually affect the lips, soft palate, tongue and larynx. Pathomechanisms, differential diagnosis and treatment of ACE-inhibitor-induced edema of the upper aerodigestive tract are described in three case reports.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235515     DOI: 10.1007/s00405-002-0481-y

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  4 in total

1.  Severe migratory Angioedema due to ACE inhibitors use.

Authors:  G Peltekis; D Palaskas; M Samanidou; A Fragakis; K Alexopoulos; A Kotsani; I Vogiatzis; E Kyrmizakis
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 2.  C1 inhibitor deficiency: consensus document.

Authors:  M M Gompels; R J Lock; M Abinun; C A Bethune; G Davies; C Grattan; A C Fay; H J Longhurst; L Morrison; A Price; M Price; D Watters
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

3.  An operation in the park bench position complicated by massive tongue swelling.

Authors:  Hiroyuki Koizumi; Satoshi Utsuki; Madoka Inukai; Hidehiro Oka; Shigeyuki Osawa; Kiyotaka Fujii
Journal:  Case Rep Neurol Med       Date:  2012-03-05

Review 4.  Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?

Authors:  Domenic A Sica; Henry R Black
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.